Fluocinolone acetonide
- Generic Name
- Fluocinolone acetonide
- Brand Names
- Capex, Derma-Smoothe/FS, Derma-smoothe FS, Dermotic, Flac, Iluvien, Neo-synalar, Otixal, Otovel, Retisert, Synalar, Tri-luma, Yutiq
- Drug Type
- Small Molecule
- Chemical Formula
- C24H30F2O6
- CAS Number
- 67-73-2
- Unique Ingredient Identifier
- 0CD5FD6S2M
- Background
Fluocinolone acetonide, with the formula 6-alpha, 9-alpha-difluoro-16-alpha, 17 alpha-acetonide, is a corticosteroid that presents a high lipophilicity. It has been used extensively in dermatological preparations and it has also been investigated thoroughly for its use in implantable corticosteroid devices. This type of device containing fluocinolone acetoni...
- Indication
Fluocinolone acetonide has been used extensively in different medical areas.
-In dermatology, it is extensively used for the relief of inflammatory dermatosis, dermatitis, psoriasis, hypertrophic tissues, keloid tissues and atopic dermatitis.
...
- Associated Conditions
- Acute Otitis Media (AOM), Allergic Skin Reaction, Atopic Dermatitis, Blisters, Chronic Disease of Skin, Dermatosis, Diabetic Macular Edema (DME), External Hemorrhoid, Fissure;Anal, Friction and Pressure Injuries, Hemorrhoids, Internal, Non-infectious Posterior Uveitis Chronic Uveitis, Otitis Externa, Perianal erythema, Pruritus, Psoriasis of the scalp, Purulent Wounds, Scab, Seborrheic dermatitis of the scalp, Skin Inflammation caused by Bacterial Infections, Skin Inflammation of the ear, Uveitis, Wound Infections, Anal eczema, Bacterial skin infections, Chronic eczematous otitis externa, Corticosteroid-responsive dermatoses
- Associated Therapies
- Postoperative Care, Perioperative management therapy, Postoperative treatment
Passage to Asia: Early Access for Innovative Therapies
Asia's complex market for innovative therapies includes varied regulatory, market access, and healthcare infrastructures. Early access programs (EAPs) like Hainan's have facilitated rapid entry for over 400 drugs and devices, with examples like Yutiq and Lorbrena gaining formal approvals and reimbursement. China's EAPs have expanded to the Greater Bay Area and beyond, while Japan, Korea, Southeast Asia, and the Middle East also use EAPs to provide early access to innovative treatments.
ANI Pharmaceuticals Reports Record Third Quarter 2024
ANI Pharmaceuticals reported Q3 2024 net revenues of $148.3 million (+12.5% YoY) and Purified Cortrophin® Gel net revenues of $52.6 million (+76.8% YoY). The company posted a net loss of $(24.2) million and adjusted non-GAAP EBITDA of $35.1 million. Diluted GAAP loss per share was $(1.27), and adjusted non-GAAP diluted earnings per share were $1.34. ANI completed the acquisition of Alimera Sciences, Inc., implemented a new capital structure reducing annual interest expense by $39.0 million, and increased 2024 guidance to $594 million to $602 million in net revenues.
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06%
ANI Pharmaceuticals launched Estradiol Gel, 0.06% after FDA approval, aiming to provide a limited-competition product with annual U.S. sales of $16.7 million.
ANI Pharmaceuticals launches generic Ketoconazole Shampoo
ANI Pharmaceuticals launches Ketoconazole Shampoo, 2%, following FDA approval, aiming to address unmet medical needs and expand its generics business. The company also completed the acquisition of Alimera Sciences, broadening its ophthalmology portfolio, and reported a robust Q2 2024 with a revenue increase of 18% to $138 million, driven by its rare disease asset and generics business. ANI Pharmaceuticals' market capitalization is $1.12 billion, with a 34.27% revenue growth over the last twelve months and a gross profit margin of 61.34%.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath